



PRESS RELEASE

Pähl, February 2013

Successful integration as top managers from the Temmler Group join the Aenova management team

The Aenova Group, one of the leading companies in the global pharmaceutical and healthcare industry, is succeeding in integrating the Temmler Group into its organisation. With immediate effect, Dr. Werner Schneider becomes a member of the top-level Aenova management team with responsibility for business development, while Matthias Utrata is responsible for tax, treasury and compliance. Both previously worked for the pharmaceutical manufacturing company Temmler, which was taken over by Aenova at the end of 2012.

The appointment of Werner Schneider and Matthias Utrata to the management team will complement its strengths and represents another step towards the successful integration of the Temmler Group. In this context, Aenova CEO Heiner Hoppmann emphasised the positive impact that the new management team members will have on the company.

“We are very pleased that Werner Schneider and Matthias Utrata have joined us. Their many years of experience of the pharmaceutical industry and their competence in this area will



enable both of them to make a significant contribution to strengthening the position of the Aenova Group,” said Hoppmann.

Werner Schneider, who has a PhD in biology, has been CEO of the Temmler Group and part of the management team since September 2006. Before this he was a member of the board of Lichtwer Pharma with responsibility for research and development, together with production and technology. Previously he held the role of scientific director and company secretary at Steigerwald Arzneimittelwerk GmbH. As CFO of the Temmler Group, Matthias Utrata was responsible for finance, IT, HR and corporate communication. On 1 February 2013, he was appointed director of tax, treasury and compliance, reporting to Frank Elsen, CFO of the Aenova Group.

About Aenova

With an annual turnover of around EUR 500 million, the Aenova Group is one of the world's leading companies in the pharmaceutical and healthcare industries. As a result of its high standards of quality, innovative technologies and clear focus on the future, Aenova has become Europe's leading provider of development, manufacturing and marketing services for medicines and dietary supplements. Its portfolio consists of solid dosage forms, which include soft gelatin capsules, hard capsules, conventional tablets, film-coated tablets, dragées and effervescent tablets, together with semi-solid and liquid dosage forms. The company's headquarters are located in Pähl near Munich. It has thirteen production sites in seven countries (Germany, Switzerland, France, Ireland, Italy, Romania and the USA) and employs a total of around 2500 people.



For further information, please contact:

Söllner Communications AG

Dominik Herrmann

Rosenkavalierplatz 5

81925 Munich

Tel.: +49 (0)89 41 94 73 13

Fax: +49 (0)89 41 94 73 26

E-mail: dominik.herrmann@w-soellner.de